Axonics® files pma supplement with the fda for non-rechargeable implantable sacral neurostimulator

Irvine, calif.--(business wire)--axonics, inc. (nasdaq: axnx), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, has filed a premarket approval (pma) supplement with the fda for its newly developed, long-lived, non-rechargeable sacral neuromodulation (snm) implantable neurostimulator (ins). axonics has designed its new non-rechargeable snm system to replicate key features of its currently marketed, fda-a
AXNX Ratings Summary
AXNX Quant Ranking